{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:20:30Z","timestamp":1771654830267,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T00:00:00Z","timestamp":1615593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T00:00:00Z","timestamp":1615593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["1095969"],"award-info":[{"award-number":["1095969"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["111424"],"award-info":[{"award-number":["111424"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00277-021-04490-3","type":"journal-article","created":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T03:02:46Z","timestamp":1615604566000},"page":"1637-1640","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine\/venetoclax and daratumumab"],"prefix":"10.1007","volume":"100","author":[{"given":"Khalid","family":"Shoumariyeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rassner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra Maria","family":"Dold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Riebl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena","family":"Pantic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Herget","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Marks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"L\u00fcbbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0405-1676","authenticated-orcid":false,"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,13]]},"reference":[{"key":"4490_CR1","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3324\/haematol.11034","volume":"92","author":"G Leone","year":"2007","unstructured":"Leone G, Pagano L, Ben-Yehuda D, Voso MT (2007) Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica. 92:1389\u20131398. https:\/\/doi.org\/10.3324\/haematol.11034","journal-title":"Haematologica."},{"key":"4490_CR2","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3324\/haematol.2015.127548","volume":"100","author":"M Engelhardt","year":"2015","unstructured":"Engelhardt M, Ihorst G, Landgren O, Pantic M, Reinhardt H, Waldschmidt J, May AM, Schumacher M, Kleber M, Wasch R (2015) Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years. Haematologica. 100:1340\u20131349. https:\/\/doi.org\/10.3324\/haematol.2015.127548","journal-title":"Haematologica."},{"key":"4490_CR3","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3324\/haematol.2016.162693","volume":"102","author":"M Engelhardt","year":"2017","unstructured":"Engelhardt M, Domm A-S, Dold SM, Ihorst G, Reinhardt H, Zober A, Hieke S, Baayen C, M\u00fcller SJ, Einsele H, Sonneveld P, Landgren O, Schumacher M, W\u00e4sch R (2017) A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 102:910\u2013921. https:\/\/doi.org\/10.3324\/haematol.2016.162693","journal-title":"Haematologica."},{"key":"4490_CR4","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.3324\/haematol.2019.238394","volume":"105","author":"SM Dold","year":"2020","unstructured":"Dold SM, Riebl V, Wider D, Follo M, Pantic M, Ihorst G et al (2020) Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma. Haematologica. 105:e523. https:\/\/doi.org\/10.3324\/haematol.2019.238394","journal-title":"Haematologica."},{"key":"4490_CR5","doi-asserted-by":"publisher","first-page":"106192","DOI":"10.1016\/j.leukres.2019.106192","volume":"85","author":"J Stratmann","year":"2019","unstructured":"Stratmann J, van Kann E, Rummelt C, Koschade S, R\u00f6llig C, L\u00fcbbert M, Schaich M, Parmentier S, Sebastian M, Chromik J, Becker von Rose A, Ballo O, Steffen B, Serve H, Brandts C, Shaid S (2019) Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: a well-tolerated and effective treatment after hypomethylating-agent failure. Leuk Res 85:106192. https:\/\/doi.org\/10.1016\/j.leukres.2019.106192","journal-title":"Leuk Res"},{"key":"4490_CR6","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/s41375-019-0587-5","volume":"34","author":"P Choudhry","year":"2020","unstructured":"Choudhry P, Mariano MC, Geng H, Martin TG, Wolf JL, Wong SW et al (2020) DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. Leukemia. 34:938\u2013941. https:\/\/doi.org\/10.1038\/s41375-019-0587-5","journal-title":"Leukemia."},{"key":"4490_CR7","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1182\/blood-2017-03-770776","volume":"129","author":"E Garc\u00eda-Guerrero","year":"2017","unstructured":"Garc\u00eda-Guerrero E, Gogishvili T, Danhof S, Schreder M, Pallaud C, P\u00e9rez-Sim\u00f3n JA, Einsele H, Hudecek M (2017) Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab. Blood. 129:3386\u20133388. https:\/\/doi.org\/10.1182\/blood-2017-03-770776","journal-title":"Blood."},{"key":"4490_CR8","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/bjh.15673","volume":"185","author":"A Bat-Erdene","year":"2019","unstructured":"Bat-Erdene A, Nakamura S, Oda A, Iwasa M, Teramachi J, Ashtar M, Harada T, Miki H, Tenshin H, Hiasa M, Fujii S, Sogabe K, Oura M, Udaka K, Kagawa K, Yoshida S, Aihara KI, Kurahashi K, Endo I, Abe M (2019) Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-\u03b1 and ATRA. Br J Haematol 185:969\u2013974. https:\/\/doi.org\/10.1111\/bjh.15673","journal-title":"Br J Haematol"},{"key":"4490_CR9","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/bjh.16228","volume":"188","author":"C Zhao","year":"2020","unstructured":"Zhao C, Jia B, Wang M, Schell TD, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Naik S, Songdej N, Sivik JM, Hohl RJ, Zeng H, Zheng H (2020) Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML. Br J Haematol 188:674\u2013684. https:\/\/doi.org\/10.1111\/bjh.16228","journal-title":"Br J Haematol"},{"issue":"9","key":"4490_CR10","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","volume":"131","author":"KL Bride","year":"2018","unstructured":"Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, Carson R, Dai Y, Devidas M, Dunsmore KP, Fuller T, Glisovic-Aplenc T, Horton TM, Hunger SP, Loh ML, Maude SL, Raetz EA, Winter SS, Grupp SA, Hermiston ML, Wood BL, Teachey DT (2018) Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 131(9):995\u2013999. https:\/\/doi.org\/10.1182\/blood-2017-07-794214","journal-title":"Blood."},{"issue":"3","key":"4490_CR11","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.3324\/haematol.2018.192757","volume":"104","author":"J Naik","year":"2019","unstructured":"Naik J, Themeli M, de Jong-Koorlar R, Ruiter RWJ, Poddighe PJ, Yuan H et al (2019) CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Haematologica. 104(3):e100\u2013e103. https:\/\/doi.org\/10.3324\/haematol.2018.192757","journal-title":"Haematologica."},{"key":"4490_CR12","doi-asserted-by":"publisher","first-page":"100202","DOI":"10.1016\/j.lrr.2020.100202","volume":"13","author":"C Berthon","year":"2020","unstructured":"Berthon C, Nudel M, Boyle EM, Goursaud L, Boyer T, Marceau A, Quesnel B (2020) Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine\/lenalidomide and daratumumab without a decrease in myeloid clone size. Leuk Res Rep 13:100202. https:\/\/doi.org\/10.1016\/j.lrr.2020.100202","journal-title":"Leuk Res Rep"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04490-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04490-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04490-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T06:17:42Z","timestamp":1620800262000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04490-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,13]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["4490"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04490-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,13]]},"assertion":[{"value":"15 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from the patient for being included in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"JJ, MR, SMD, VR, MP, GH, RM, ML have no financial or other relationships that might lead to a conflict of interest. KS has received travel support from Abbvie and consultancy fees from Novartis. RW has received research and travel support from Sanofi, Gilead, Jazz, Celgene, and Amgen and has received consultancy fees from Sanofi, Pfizer, Gilead, Novartis, Amgen, and Takeda. ME has received educational and trial support from Amgen, Takeda, BMS, Janssen, and Novartis, in all unrelated to this case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}